by
Lynn Shapiro, Writer | November 24, 2008
Northwestern researchers will come up with findings about the role of medical technology in diagnosing and treating obstructive sleep apnea. The team will explore cost-effectiveness as well as who has access to diagnostic and therapeutic technology to treat sleep apnea.
Researchers will build a predictive model to assess the effects of improved diagnosis and treatment of the condition that can be used for future policy and technology development.
Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Tufts University Measuring the Value of Diagnostic Technology
Diagnostic testing continues to be one of the fastest growing fields in health care, driven in part by evidence that these technologies improve survival for patients by assisting in the diagnosis and treatment of diseases such as cancer and heart disease.
The value of diagnostic technology, however, is often poorly documented or understood. The nation's escalating health care costs have prompted policy-makers to call for stronger clinical and economic evidence of improved patient outcomes and cost-effectiveness before expensive diagnostic tools, such as imaging systems, are used.
University of Houston to Analyze How Patients Value Genomic Devices
Personalized medicine is increasingly being adopted into clinical practice, but there has been little research to understand how testing and the prescribing of drugs will be adopted by patients.
Researches will analyze the willingness of patients from different socio-economic backgrounds to use genomic devices for tailoring drug-prescription, including the willingness to pay for novel genomic diagnostics.
Researchers will examine patient preferences when it comes to personalized medicine and the trade-offs that patients make in deciding whether to use pharmacogenomic testing, which identifies patients who are likely to have the most (or least) toxicity from a drug. The findings are expected to contribute to understanding of which technologies are used,how they are incorporated into medical practice, and who has access to this sophisticated technology.
Back to HCB News
